April 2026 Section 232 Tariff Update: What New Steel, Aluminum, Copper, and Pharmaceutical Import Rules Mean for U.S. Shippers

Executive Summary 

A new round of Section 232 actions just made tariff planning more operational and more expensive for many U.S. importers. For metals, the government is no longer focused only on steel, aluminum, or copper content. In many cases, it is now assessing duty against the full customs value of the imported product, with revised annex lists determining whether goods face 50%, 25%, temporary 15%, reduced 10%, or no Section 232 metals tariff at all. For patented pharmaceuticals, the White House created a separate framework with 100%, 20%, 15%, 10%, or 0% outcomes depending on company commitments, trade-deal status, and product type. This is now a landed-cost, sourcing, classification, and execution story, not just a policy headline.

Intro

Somewhere between when you booked that freight and now, the cost of landing it changed. Not because carriers raised rates or origin prices moved. Because the April 2026 Section 232 expansion rewrote the duty exposure on finished goods across categories that most importers never associated with steel and aluminum tariffs.

Copper is in the framework now. Patented pharmaceuticals carry their own separate tariff structure. But the provision hitting hardest is the one very few quoted around: Customs can assess Section 232 duties against the full customs value of an imported product, not just its metal content. 

We went through the proclamations, the annexes, and the Federal Register filings line by line, and broke them down in plain English for you.

What Changed, and When Importers Need to Care

Two completely different Section 232 tariff frameworks landed on top of each other, each with its own product scope, effective dates, rate tiers, and exception logic. One covers metals. The other covers patented pharmaceuticals. 

Metals: Broader Scope, Full-Value Assessment, Five Rate Tiers

The metals proclamation kicks in for covered goods entered for consumption, or withdrawn from a warehouse for consumption, at 12:01 a.m. EDT on April 6, 2026. Steel and aluminum were already in the Section 232 universe. Copper joins them now.

The bigger operational change is how Customs calculates the duty. Before April 6, Section 232 duties on metals applied to the metal content. Now they apply to the full customs value of the imported good. That distinction will hit hardest on derivative products where the metal is one component of a higher-value unit.

Here's how the rate tiers break down:

• 50% on Annex I-A articles
• 25% on Annex I-B products
• 15% on certain metal-intensive industrial and grid equipment listed under Annex III, a temporary rate that expires December 31, 2027
• 10% on products made entirely with U.S.-origin metal
• 0% on products containing 15% or less steel, aluminum, or copper by composition, per the White House fact sheet. Those fall outside Section 232 metals tariffs entirely.

Annex II products are removed from the metals tariffs altogether.

Pharmaceuticals: A Whole Different Animal

The pharma framework runs on a completely separate track.

Patented pharmaceuticals and associated ingredients listed under Annex I face a baseline rate of 100%. That number drops based on what the manufacturing company commits to and where it stands with the U.S. government:

• 100% baseline for patented pharma and associated ingredients
• 20% for products from companies with approved onshoring plans
• 0% for companies that hold both an approved onshoring plan and an MFN pricing agreement, valid through January 20, 2029
• 15% for products originating from the EU, Japan, Korea, Switzerland, or Liechtenstein under trade-deal treatment
• 10% for UK-origin products under the current framework

Generics, biosimilars, and their associated ingredients sit outside the Section 232 pharma tariffs for now. That word "for now" is doing a lot of work in that sentence.

Timing also splits by company. Pharma tariffs take effect July 31, 2026, for companies listed in Annex III. Everyone else faces a September 29, 2026, effective date.  

Three Reasons This Hits Beyond Raw Materials and Pharma Headlines

What’s arguably just as, if not more important, is understanding how these proclamations interact with a specific product mix, a specific classification, and a specific sourcing strategy.  

You Don't Have to Import Metal to Owe Metal Tariffs

The full-value assessment change is the sleeper. If your finished good or derivative product falls under a covered HTS heading, Customs applies the Section 232 duty to the entire customs value, not the steel, aluminum, or copper portion. A retailer importing fixtures, a manufacturer bringing in equipment, a supplier moving electrical infrastructure: none of them think of themselves as metal importers. The duty bill says otherwise.

The Rate You Heard Is Probably Not Your Rate

"50% tariff on metals" made the headlines. The operational reality has five tiers, four annexes, a sunset date, and a domestic-origin exception. Some products sit at 25%. Some qualify for 15% through 2027. Some dropped off the list entirely. The only question that matters for your operation is specific: which annex, which product, which origin, which entry date, which exception applies. Getting that wrong in either direction costs money.

Pharma Needs Its Own Decision Tree

The pharmaceutical framework stacks five variables on top of each other: patented versus generic status, onshoring plan approval, MFN pricing agreements, trade-deal country treatment, and specialty-product exemptions. Medical, healthcare, and life sciences shippers who rely on a single "pharma tariff" assumption are going to be surprised. Product-level and company-level analysis is the only way through.

Where Importers Are Most Likely to Get Caught Off Guard

What tends to bite importers is what’s buried deeper in the proclamations: the classification triggers that moved, the origin rules that tightened, the FTZ provisions that changed without fanfare. Four risk zones stand out, and each one can cost you before you realize the exposure exists.

Classification Assumptions That No Longer Hold

Whatever HTS treatment you relied on last month may not survive the new annex structures. Products now sort into distinct buckets: articles, derivatives, removed items, and temporary-relief items. Each one carries a different rate or drops out of scope entirely. Most importers will feel the first sting right here, when a product lands in a different bucket than expected.  

Origin Claims Without Proof to Back Them Up

Reduced metals rates hinge on where steel was melted and poured, or where aluminum and copper were smelted and cast. Reduced pharma rates depend on company-specific agreements and country-level trade-deal status. Supplier affidavits, bills of materials, production records, origin certificates: all of it carries real weight now. If your documentation can't support the origin claim, the reduced rate vanishes, and the baseline applies.

FTZ and Drawback Rules That Shrank Overnight

Covered products admitted into a U.S. foreign trade zone after the effective date enter under privileged foreign status only. Drawback eligibility narrows to limited cases tied to specific annex classifications, AD/CVD status, trade-agreement treatment, and metal-origin rules. Tariff planning for these entries just became a sequencing and facility problem, not a filing exercise.

A Buried Provision That Packaging-Heavy Importers Need to Read

The administration reserved the authority to pull metal containers into the Section 232 scope even when those containers hold non-metal goods. Consumer-goods shippers, food importers, anyone moving product in steel or aluminum packaging: that one line in the proclamation deserves a careful read before it turns into an unexpected duty bill.

What This Means for Your Operation

The risk zones above apply broadly. But the way they hit depends on what you move, where you source it, and how your pricing holds up under new duty exposure.  

Manufacturers

Your exposure lives in production inputs, fabricated components, replacement parts, tooling, and imported machinery. The duty cost alone stings. But the deeper problem is that procurement models, production schedules, and customer pricing were all built on assumptions about metal-content-based assessment. Full customs value changes the unit economics on every covered import. If nobody updated those assumptions, your margins already eroded.

Retailers and Consumer-Goods Suppliers

Finished goods, fixtures, packaging, display systems, housewares, electrical products: the Section 232 expansion touches all of them. The White House framework sorts covered items into articles, derivative articles, temporary-relief industrial equipment, and low-metal-content products. Some goods get more expensive. Some fall out of scope entirely. Blanket assumptions about what's covered will cost you either way. Re-screen the product mix now.

Medical and Healthcare Shippers

The pharma tariffs target patented products and associated ingredients, not generics or biosimilars. That distinction makes product segmentation and company-status verification critical before the July 31 and September 29 deadlines arrive. Supplier communication and temperature-controlled network planning need to start now, not after the first duty bill lands.

Paper, Lumber, Cotton, and Industrial Suppliers

Your core commodity may sit outside Section 232 scope. Your equipment, containers, fabricated supports, electrical systems, and packaging probably don't. Cross-functional review across sourcing, finance, logistics, and customs belongs on the calendar this week.

What Importers Should Do Right Now

The proclamations are published. The effective dates are set. The window between now and your next Customs entry is the window that matters. Five moves belong at the top of the list.

‍

1. Map Your Affected SKUs and Purchase Orders: Build a working list of products that fall under Annex I-A, I-B, II, or III for metals, and separately flag patented, generic, biosimilar, and specialty pharmaceutical items. Nobody should be setting budget expectations without annex-level screening.  
2. Rebuild Landed-Cost Scenarios Under Full Customs Value: Prior duty calculations based on metal-content assessment will understate your exposure, possibly by a lot. Finance, procurement, and logistics need one shared forecast. 
3. Collect Origin and Production Documentation Now: Reduced Section 232 rates depend on specific origin facts: where metal was melted and poured, where it was smelted and cast, which onshoring or trade-deal conditions apply. Supplier certifications, manufacturing records, and country-of-origin evidence take time to gather. Waiting until the entry is ready won't help.
4. Review Your FTZ, Warehouse, and Drawback Strategy: The proclamation changed how covered goods get admitted into foreign trade zones and narrowed drawback eligibility to limited conditions. If your tariff planning relies on any of those tools, revisit the approach before the effective date, not after.
5. Stand Up a Cross-Functional Escalation Path: Customs brokerage, freight forwarding, warehousing, procurement, finance, and customer communication all touch this problem. Align them now.  

What Mallory Alexander Brings to This Moment

Tariff changes like these don't stay in the compliance department. They ripple into freight routing, warehouse timing, entry strategy, and customer pricing. Solving one piece without the others just moves the problem downstream.

Mallory Alexander operates as a licensed customs broker, global freight forwarder, and warehousing provider under one roof, with 31 locations worldwide and over two million square feet of U.S. warehouse space. That matters here because the Section 232 expansion demands answers that connect classification decisions to actual freight execution, storage planning, and delivery timelines. 

A customs ruling that doesn't account for your FTZ strategy helps no one. A freight plan that ignores your duty exposure helps even less. When policy changes hit tariff scope, customs valuation, routing, and landed cost all at once, you need a team that can work the problem from entry filing through final delivery.

Contact Mallory Alexander to get started today.